4 ms·
There are a number of reasons other than "cui bono" why AZ is more in focus. First one: Astrazeneca (and for what it's worth, also Sputnik and Sinovac) uses a
by mschuster91 6y ago
There are a number of reasons other than "cui bono" why AZ is more in focus.
First one: Astrazeneca (and for what it's worth, also Sputnik and Sinovac) uses a vectorvirus with all problems that come with that (as the "carrier" virus is still somewhat alive).
Second one: Biontech/Moderna got used for the elderly population in many countries as they were the first to market, whereas AZ was mainly used for younger care staff in countries like Germany (and UK, which almost exclusively used AZ, prioritized the elderly, too). Given that the clotting issue seems to be drastically more prevalent in young women (which is the common demographics for care staff) it's not surprising to see a rush of clotting cases prop up in Germany and not in UK. An uninformed at best and clickbait/scaremongering/ragebait-interested at worst press is bound to take that cheap bait.
Third one: AZ completely fucked up its deliveries to the EU and had massive issues with intransparency, which leads to even more, this time legitimate and massive, press and political attention.
Side note: AZ vaccine was developed by non-profit Oxford University, but AZ is still a for-profit company!
(Also, if I would have the chance of an AZ dose I'd gladly take it, but here in Germany our politicians are incompetent buffoons so God knows when I'll get a shot)